Dr. Hitchcock serves as the Chief Science Officer for Crown Laboratories and oversees Clinical Development, Medical Affairs and Research & Development for Crown and its subsidiaries. He is also the Founder of Xycrobe Therapeutics Inc. (http://www.xycrobe.com) and served as its Chief Executive Officer. Additionally, Dr. Hitchcock served as the Acting Chief Scientific Officer and Vice President of Clinical & Medical Affairs at Bellus Medical from its inception in 2013 up to the acquisition by Crown Laboratories.
Previous to his work in the industry, Dr. Hitchcock performed research at Weill Cornell Medical College, where he studied multiple myeloma genetics. He also performed post-doctoral research in tissue engineering and regenerative medicine at Duke University and Yale University. Following his post-doctoral studies, Dr. Hitchcock began working in the field of dermatology at companies like Suneva Medical and Ulthera, as well as consultancy for companies such as Boehringer Ingelheim and Bayer.
Dr. Hitchcock has more than 15 years of research experience, including Basic Science, Proof-of-Concept, Pre-Clinical and Clinical Research across several therapeutic areas such as Cardiology, Oncology, Gene Therapy, Plastic/Facial Plastic Surgery, Dermatology and Aesthetic Medicine. Dr. Hitchcock earned his Ph.D. in Genetics from Clemson University and completed post-doctoral trainings at Duke University and Yale University in Biomedical Engineering, Vascular Biology and Therapeutics